Cargando…

Optimization of Radiolabeling of a [(90)Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation

SIMPLE SUMMARY: For high-risk patients, particularly young or elderly patients, with diseases of the hematopoietic cells, allogeneic hematopoietic cell transplantation (HCT) is often the only potentially curative treatment option. In preparation, high-dose chemotherapy and, in selected cases, extern...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winter, Gordon, Hamp-Goldstein, Carmen, Fischer, Gabriel, Kletting, Peter, Glatting, Gerhard, Solbach, Christoph, Herrmann, Hendrik, Sala, Elisa, Feuring, Michaela, Döhner, Hartmut, Beer, Ambros J., Bunjes, Donald, Prasad, Vikas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377894/ https://www.ncbi.nlm.nih.gov/pubmed/37509321 http://dx.doi.org/10.3390/cancers15143660

Ejemplares similares

Physiologically Based Pharmacokinetic Modeling Is Essential in (90)Y-Labeled Anti-CD66 Radioimmunotherapy
por: Kletting, Peter, et al.
Publicado: (2015)

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with (90)Y and (111)In for domestic radioimmunotherapy and radioscintigraphy of Non-Hodgkin’s Lymphoma
por: Gholipour, Nazila, et al.
Publicado: (2014)

Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
por: Uccelli, Licia, et al.
Publicado: (2017)

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model
por: Begum, Nusrat J., et al.
Publicado: (2019)

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
por: Zaid, Nouran R. R., et al.
Publicado: (2021)

Comparison of Quantification of Target-Specific Accumulation of [(18)F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI
por: Löffler, Jessica, et al.
Publicado: (2021)

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies
por: Dillman, R. O.
Publicado: (2006)

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for (177)Lu-Labeled PSMA-Targeting Peptides
por: Kletting, Peter, et al.
Publicado: (2016)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

A population-based method to determine the time-integrated activity in molecular radiotherapy
por: Hardiansyah, Deni, et al.
Publicado: (2021)

Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging
por: Löffler, Jessica, et al.
Publicado: (2022)

Dynamic Metabolic Changes during the First 3 Months after (90)Y-Ibritumomab Tiuxetan Radioimmunotherapy
por: Takahashi, Miwako, et al.
Publicado: (2014)

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.
por: Neagoie, Adela, et al.
Publicado: (2021)

Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation
por: Hütter-Krönke, Marie Luise, et al.
Publicado: (2022)

Anti-CD45 Radioimmunotherapy with (90)Y but Not (177)Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model
por: Orozco, Johnnie J., et al.
Publicado: (2014)

Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015)

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
por: Baur, Benjamin, et al.
Publicado: (2014)

Quantitative analysis of regional distribution of tau pathology with (11)C-PBB3-PET in a clinical setting
por: Yousefzadeh-Nowshahr, Elham, et al.
Publicado: (2022)

Evaluation of Efficacy of Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
por: Sugyo, Aya, et al.
Publicado: (2015)

Radioimmunotherapy of pancreatic cancer xenografts in nude mice using (90)Y-labeled anti-α(6)β(4) integrin antibody
por: Aung, Winn, et al.
Publicado: (2016)

Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept
por: Hardiansyah, Deni, et al.
Publicado: (2023)

Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model
por: Hardiansyah, Deni, et al.
Publicado: (2022)

Multi-Modal PET and MR Imaging in the Hen’s Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial In Vivo Testing of Target-Specific Radioligands
por: Winter, Gordon, et al.
Publicado: (2020)

Combined treatment of pancreatic cancer xenograft with (90)Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
por: Aung, Winn, et al.
Publicado: (2017)

Pretargeted adjuvant radioimmunotherapy with Yttrium-90-biotin in malignant glioma patients: A pilot study
por: Grana, C, et al.
Publicado: (2002)

Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
por: Sabanathan, Dhanusha, et al.
Publicado: (2021)

Preclinical PET and MR Evaluation of (89)Zr- and (68)Ga-Labeled Nanodiamonds in Mice over Different Time Scales
por: Winter, Gordon, et al.
Publicado: (2022)

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation
por: Hütter-Krönke, Marie Luise, et al.
Publicado: (2023)

A radiolabeled antibody targeting CD123(+) leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML
por: Leyton, Jeffrey V., et al.
Publicado: (2015)

Immunostimulatory effects of radioimmunotherapy
por: Constanzo, Julie, et al.
Publicado: (2022)

The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres
por: Westcott, Mark A., et al.
Publicado: (2016)

Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
por: Yoshida, Chisato, et al.
Publicado: (2013)

A (90)Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy
por: Fujiwara, Kentaro, et al.
Publicado: (2014)

Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry
por: Hohloch, Karin, et al.
Publicado: (2020)

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule
por: Maaß, Christian, et al.
Publicado: (2016)

Pretargeted Molecular Imaging and Radioimmunotherapy
por: Goldenberg, David M., et al.
Publicado: (2012)

Radioimmunotherapy: a brief overview
por: Ng, DCE
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_mqosdnab2sa69l8u35br9f1nv0